QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Competitors

$23.95
-0.02 (-0.08%)
(As of 06/8/2023 ET)
Compare
Today's Range
$23.37
$24.26
50-Day Range
$18.66
$25.21
52-Week Range
$15.08
$27.44
Volume
937,776 shs
Average Volume
640,757 shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.83

KDNY vs. AMLX, XNCR, VRNA, IRWD, RCKT, FGEN, ZNTL, SLRN, GERN, and DICE

Should you be buying Chinook Therapeutics stock or one of its competitors? The main competitors of Chinook Therapeutics include Amylyx Pharmaceuticals (AMLX), Xencor (XNCR), Verona Pharma (VRNA), Ironwood Pharmaceuticals (IRWD), Rocket Pharmaceuticals (RCKT), FibroGen (FGEN), Zentalis Pharmaceuticals (ZNTL), Acelyrin (SLRN), Geron (GERN), and DICE Therapeutics (DICE). These companies are all part of the "pharmaceutical preparations" industry.

Chinook Therapeutics vs.

Chinook Therapeutics (NASDAQ:KDNY) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.

Chinook Therapeutics received 11 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Amylyx Pharmaceuticals an outperform vote while only 60.47% of users gave Chinook Therapeutics an outperform vote.

CompanyUnderperformOutperform
Chinook TherapeuticsOutperform Votes
26
60.47%
Underperform Votes
17
39.53%
Amylyx PharmaceuticalsOutperform Votes
15
71.43%
Underperform Votes
6
28.57%

Chinook Therapeutics has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Chinook Therapeutics' net margin of -4,114.05%. Chinook Therapeutics' return on equity of -47.13% beat Amylyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Chinook Therapeutics -4,114.05% -47.13% -37.47%
Amylyx Pharmaceuticals N/A -57.84% -49.40%

Chinook Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chinook Therapeutics$6.13 million256.76-$187.87 million-$3.19-7.38
Amylyx Pharmaceuticals$22.23 million78.81-$198.38 million-$2.48-10.52

Chinook Therapeutics currently has a consensus price target of $35.83, suggesting a potential upside of 52.29%. Amylyx Pharmaceuticals has a consensus price target of $50.17, suggesting a potential upside of 93.17%. Given Amylyx Pharmaceuticals' higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Chinook Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chinook Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Amylyx Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

93.9% of Chinook Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. 16.8% of Chinook Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 8 more articles in the media than Chinook Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 3 mentions for Chinook Therapeutics. Chinook Therapeutics' average media sentiment score of 0.55 beat Amylyx Pharmaceuticals' score of 0.40 indicating that Chinook Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Chinook Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amylyx Pharmaceuticals
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Chinook Therapeutics beats Amylyx Pharmaceuticals on 12 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KDNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KDNY vs. The Competition

MetricChinook TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.57B$5.96B$4.59B$6.27B
Dividend YieldN/A2.59%2.37%6.38%
P/E Ratio-7.384.5094.7912.16
Price / Sales256.76331.313,431.0788.98
Price / CashN/A20.7191.06107.03
Price / Book3.414.814.715.31
Net Income-$187.87M$191.69M$117.69M$192.96M
7 Day Performance-4.89%2.69%2.64%3.85%
1 Month Performance11.46%1.37%1.97%5.16%
1 Year Performance33.01%14.61%11.38%1.70%

Chinook Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMLX
Amylyx Pharmaceuticals
2.6479 of 5 stars
$24.04
-3.2%
$50.17
+108.7%
+117.7%$1.62B$22.23M-9.6934High Trading Volume
XNCR
Xencor
2.0671 of 5 stars
$27.09
-0.6%
$45.33
+67.3%
+23.6%$1.64B$164.58M-11.58254Positive News
VRNA
Verona Pharma
1.8301 of 5 stars
$20.90
-2.3%
$29.33
+40.4%
+325.7%$1.65B$460,000.00-21.7724Analyst Report
Positive News
IRWD
Ironwood Pharmaceuticals
2.1404 of 5 stars
$10.75
-0.6%
$15.67
+45.7%
-4.8%$1.66B$410.60M10.64219
RCKT
Rocket Pharmaceuticals
2.3521 of 5 stars
$20.65
-2.6%
$51.09
+147.4%
+70.7%$1.66BN/A-6.16151
FGEN
FibroGen
2.1416 of 5 stars
$17.11
+2.5%
$23.40
+36.8%
+63.1%$1.67B$140.73M-5.23566Options Volume
News Coverage
ZNTL
Zentalis Pharmaceuticals
1.4761 of 5 stars
$26.46
-11.9%
$46.60
+76.1%
-10.5%$1.57BN/A-6.17177Analyst Report
High Trading Volume
SLRN
Acelyrin
1.9689 of 5 stars
$18.17
-5.7%
N/AN/A$1.68BN/A0.00N/AGap Up
GERN
Geron
1.9863 of 5 stars
$3.32
+2.2%
$5.00
+50.6%
+159.9%$1.69B$600,000.00-9.7669
DICE
DICE Therapeutics
2.0417 of 5 stars
$31.46
-4.1%
$62.60
+99.0%
+117.2%$1.50B$1.13M-14.4346

Related Companies and Tools

This page (NASDAQ:KDNY) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -